Literature DB >> 27006184

Immunochemical faecal occult blood testing to screen for colorectal cancer: can the screening interval be extended?

Ulrike Haug1,2, Esmée J Grobbee3, Iris Lansdorp-Vogelaar4, Manon C W Spaander3, Ernst J Kuipers3.   

Abstract

OBJECTIVE: Colorectal cancer (CRC) screening programmes based on faecal immunochemical testing for haemoglobin (FIT) typically use a screening interval of 2 years. We aimed to estimate how alternative FIT strategies that use a lower than usual positivity threshold followed by a longer screening interval compare with conventional strategies.
METHODS: We analysed longitudinal data of 4523 Dutch individuals (50-74 years at baseline) participating in round I of a one-sample FIT screening programme, of which 3427 individuals also participated in round II after 1-3 years. The cohort was followed until 2 years after round II. In both rounds, a cut-off level of ≥50 ng haemoglobin (Hb)/mL buffer (corresponding to 10 µg Hb/g faeces) was used, representing the standard scenario. We determined the cumulative positivity rate (PR) and the numbers of subjects diagnosed with advanced adenomas (N_AdvAd) and early stage CRC (N_earlyCRC) in the cohort over two rounds of screening (standard scenario) and compared it with hypothetical single-round screening with use of a lower cut-off and omission of the second round (alternative scenario).
RESULTS: In the standard scenario, the cumulative (ie, round I and II combined) PR, N_AdvAd and N_earlyCRC were 13%, 180% and 26%, respectively. In alternative scenarios using a cut-off level of respectively ≥11 and ≥22 ng/HbmL buffer (corresponding to 2 and 4 µg Hb/g faeces), the PRs were 18% and 13%, the N_AdvAd were 180 and 162 and the N_earlyCRC ranged between 22-27 and 22-26.
CONCLUSIONS: The diagnostic yield of FIT screening using a lowered positivity threshold in combination with an extended screening interval (up to 5 years) may be similar to conventional FIT strategies. This justifies and motivates further research steps in this direction. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  COLORECTAL CANCER SCREENING

Mesh:

Substances:

Year:  2016        PMID: 27006184     DOI: 10.1136/gutjnl-2015-310102

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  5 in total

1.  Faecal immunochemical test to triage patients with abdominal symptoms for suspected colorectal cancer in primary care: review of international use and guidelines.

Authors:  Marije van Melle; Samir I S Yep Manzano; Hugh Wilson; Willie Hamilton; Fiona M Walter; Sarah E R Bailey
Journal:  Fam Pract       Date:  2020-10-19       Impact factor: 2.267

2.  Effect of Sex, Age, and Positivity Threshold on Fecal Immunochemical Test Accuracy: A Systematic Review and Meta-analysis.

Authors:  Kevin Selby; Emma H Levine; Cecilia Doan; Anton Gies; Hermann Brenner; Charles Quesenberry; Jeffrey K Lee; Douglas A Corley
Journal:  Gastroenterology       Date:  2019-08-22       Impact factor: 22.682

3.  Selecting a Cut-off for Colorectal Cancer Screening With a Fecal Immunochemical Test.

Authors:  Hermann Brenner; Simone Werner
Journal:  Clin Transl Gastroenterol       Date:  2017-08-03       Impact factor: 4.488

4.  Fecal occult blood versus DNA testing: indirect comparison in a colorectal cancer screening population.

Authors:  Hermann Brenner; Hongda Chen
Journal:  Clin Epidemiol       Date:  2017-07-13       Impact factor: 4.790

Review 5.  Colorectal Cancer Screening-Who, How, and When?

Authors:  Roisin Bevan; Matthew D Rutter
Journal:  Clin Endosc       Date:  2018-01-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.